Latigo Biotherapeutics Stock Forecast
NASDAQ: LTGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 14.79 0.00%
LTGO analyst consensus
Consensus (4 analysts)
none
Avg. price target
$52.25+253.28%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Latigo Biotherapeutics (2026-10-08), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $52.25, with a high estimate of $73.00 and a low estimate of $36.00. The average target implies upside of 253.3% from the current price of $14.79.
The spread between the highest and lowest targets is 102.8%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for LTGO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $36.00 | +143.41% |
| Average target | $52.25 | +253.28% |
| High target | $73.00 | +393.58% |